Evidence map›Paper›PMID 40373089›Full record

ArticlePloS one2025

Autoencoder techniques for survival analysis on renal cell carcinoma.

Iñigo Sanz Ilundain, Laura Hernández-Lorenzo, Cristina Rodríguez-Antona, Jesús García-Donas, José L Ayala

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Iñigo Sanz IlundainComplutense University of Madrid, Madrid, Spain.
Laura Hernández-LorenzoComplutense University of Madrid, Madrid, Spain.
Cristina Rodríguez-AntonaCSIC/UAM, Madrid, Spain.
Jesús García-DonasHM CIOCC Madrid, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.
José L AyalaComplutense University of Madrid, Madrid, Spain.ORCID 0000-0001-7236-5330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival is the gold standard in oncology when determining the real impact of therapies in patients outcome. Thus, identifying molecular predictors of survival (like genetic alterations or transcriptomic patterns of gene expression) is one of the most relevant fields in current research. Statistical methods and metrics to analyze time-to-event data are crucial in understanding disease progression and the effectiveness of treatments. However, in the medical field, data is often high-dimensional, complicating the application of such methodologies. In this study, we addressed this challenge by compressing the high-dimensional transcriptomic data of patients treated with immunotherapy (avelumab + axitinib) and a TKI (sunitinib) into latent, meaningful features using autoencoders. We applied a semi-parametric statistical approach based on the COX Proportional Hazards model, coupled with Breslow's estimator, to predict each patient's Progression-Free Survival (PFS) and determine survival functions. Our analysis explored various penalty configurations and their combinations. Given the complexity of transcriptomic data, we extended our model to incorporate both tabular data and its graph variant, where edges represent protein-protein interactions between genes, offering a more insightful approach. Recognizing the interpretability challenges inherent in neural networks, particularly autoencoders, we analyzed the mutual information between genes in the original data and their latent feature representations to clarify which genes are most associated with specific latent variables. The results indicate that different types of autoencoders are better suited for different tasks: denoising autoencoders excel at accurate reconstruction, while the sparse variant is more effective at producing meaningful representations. Additionally, combining these penalties enhances both reconstruction quality and the interpretability of latent features. The interpretable models identified genes such as LRP2 and ACE2 as highly relevant to renal cell carcinoma. This research underscores the utility of autoencoders in managing high-dimensional data problems.

Indexed as

AutoencoderCarcinoma, Renal CellKidney NeoplasmsAntibodies, Monoclonal, HumanizedAxitinibHumansImmunotherapyProgression-Free SurvivalProportional Hazards ModelsSunitinibSurvival AnalysisTranscriptomeAntibodies, Monoclonal, HumanizedAxitinibSunitinib

Identifiers

PMID40373089
PMCPMC12080797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.